Russell Investments Group Ltd. Lowers Holdings in The Beauty Health Company $SKIN

Russell Investments Group Ltd. reduced its position in The Beauty Health Company (NASDAQ:SKIN) by 31.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 58,213 shares of the company’s stock after selling 26,118 shares during the period. Russell Investments Group Ltd.’s holdings in Beauty Health were worth $78,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. ProShare Advisors LLC lifted its stake in shares of Beauty Health by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 20,959 shares of the company’s stock valued at $33,000 after purchasing an additional 6,896 shares in the last quarter. Barclays PLC lifted its stake in shares of Beauty Health by 11.1% in the 4th quarter. Barclays PLC now owns 117,920 shares of the company’s stock valued at $187,000 after purchasing an additional 11,817 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Beauty Health in the 4th quarter valued at about $25,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Beauty Health by 19.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 114,147 shares of the company’s stock valued at $182,000 after purchasing an additional 18,400 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of Beauty Health in the 4th quarter valued at about $64,000. 93.26% of the stock is owned by institutional investors and hedge funds.

Beauty Health Price Performance

Shares of NASDAQ:SKIN opened at $2.00 on Thursday. The company has a quick ratio of 4.15, a current ratio of 5.15 and a debt-to-equity ratio of 4.91. The Beauty Health Company has a 52-week low of $0.78 and a 52-week high of $2.56. The company has a 50 day moving average of $1.95 and a two-hundred day moving average of $1.58. The company has a market capitalization of $253.64 million, a price-to-earnings ratio of -7.14 and a beta of 1.23.

Beauty Health (NASDAQ:SKIN) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.09. Beauty Health had a negative net margin of 6.13% and a negative return on equity of 32.82%. The company had revenue of $78.20 million during the quarter, compared to the consensus estimate of $74.67 million. Beauty Health has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, analysts forecast that The Beauty Health Company will post -0.25 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on SKIN shares. Wall Street Zen raised Beauty Health from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Stifel Nicolaus lifted their price objective on Beauty Health from $3.00 to $4.00 and gave the company a “hold” rating in a research note on Friday, August 1st. Two research analysts have rated the stock with a Hold rating, According to MarketBeat, Beauty Health presently has an average rating of “Hold” and an average target price of $2.63.

Beauty Health Profile

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.